Clinical Trials Browser

Phase 1/2 × INDUSTRY × L-BLP25 × Clear all

NCT00960115 2015-10-21

Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Phase 1/2 Completed

178 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung